EDGE*TEST relies on Edge Technology and our proprietary algorithm to statistically differentiate between diseased and healthy tissue and cell samples. The EDGE*TEST method has been shown to be applicable to a broad range of diseases and dysfunctions with significant benefits:

• Since the method relies on the ratio of markers within internal Edge fractions of the sample, the method is INDEPENDENT of sample amount
• The method DOES NOT require internal or external standards
• Each sample is analyzed in its ENTIRETY for a defined marker

The utility of EDGE*TEST has been demonstrated in the evaluation of a predictive biomarker for prostate cancer (PCa). Within a group of 24 patients who underwent needle biopsy for PCa, EDGE*TEST data from initial biopsy showed increased specificity and sensitivity when compared with traditional tests (PSA and PCA3 plus). Negative PCa biopsy patients were followed up for 18 months to compare predictive value of EDGE*TEST to traditional screening and biopsy. In summary:

• EDGE*TEST predictability based on the initial biopsy is significantly superior to traditional tests
• After 18 months follow-up, EDGE*TEST still shows high predictive data of benign and not cancer
• EDGE*TEST provides well-correlated data on whether a prostate will contain cancerous tissue
• The method only needs 2 biopsy cores vs. 10-12 normally used
• EDGE*TEST provides the opportunity to significantly improve the detection, assessment and management of prostate cancer